Cargando…

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs

Metabolic dysfunction-associated steatotic liver disease (MASLD) is considered a “multisystem” disease that simultaneously suffers from metabolic diseases and hepatic steatosis. Some may develop into liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Given the close connection between met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Baoqiang, Wei, Yuankui, Zhang, Mingming, Yang, Shiyu, Tong, Rongsheng, Li, Wenyuan, Long, Enwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665502/ https://www.ncbi.nlm.nih.gov/pubmed/38027027 http://dx.doi.org/10.3389/fphar.2023.1286449

Ejemplares similares

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
por: Staufer, Katharina, et al.
Publicado: (2023)

Machine Learning Approaches to Predict Risks of Diabetic Complications and Poor Glycemic Control in Nonadherent Type 2 Diabetes
por: Fan, Yuting, et al.
Publicado: (2021)

A machine learning-based risk warning platform for potentially inappropriate prescriptions for elderly patients with cardiovascular disease
por: Xingwei, Wu, et al.
Publicado: (2022)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
por: Paklar, Natasa, et al.
Publicado: (2023)

The impact of cortisol in steatotic and non‐steatotic liver surgery
por: Cornide‐Petronio, María Eugenia, et al.
Publicado: (2017)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
por: Eskridge, Wayne, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
por: Chan, Wah-Kheong, et al.
Publicado: (2023)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
por: Takahashi, Yoshihisa, et al.
Publicado: (2023)

An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
por: Kendall, Timothy J., et al.
Publicado: (2023)

The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
por: Backer, Sean, et al.
Publicado: (2023)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
por: Kim, Gi-Ae, et al.
Publicado: (2023)

Molecular mechanisms of ferroptosis and the potential therapeutic targets of ferroptosis signaling pathways for glioblastoma
por: Zhang, Meng, et al.
Publicado: (2022)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Mitogen Activated Protein Kinases in Steatotic and Non-Steatotic Livers Submitted to Ischemia-Reperfusion
por: Jiménez-Castro, Mónica B., et al.
Publicado: (2019)

Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
por: Da, Ben L, et al.
Publicado: (2022)

Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients
por: Šeda, Ondrej, et al.
Publicado: (2019)

The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors
por: Micó-Carnero, Marc, et al.
Publicado: (2022)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
por: Huang, Yunqian, et al.
Publicado: (2023)

Identification of a novel ferroptosis-related gene signature associated with prognosis, the immune landscape, and biomarkers for immunotherapy in ovarian cancer
por: Liu, Yilong, et al.
Publicado: (2022)

Ferroptosis as an emerging therapeutic target in liver diseases
por: Lu, Yuzhen, et al.
Publicado: (2023)

The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
por: Avalos-de León, Cindy G., et al.
Publicado: (2019)

The Mechanism of Ferroptosis and Applications in Tumor Treatment
por: Lin, Xinyue, et al.
Publicado: (2020)

How to Preserve Steatotic Liver Grafts for Transplantation
por: Patrono, Damiano, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
por: Moon, Joon Ho, et al.
Publicado: (2023)

Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
por: Lai, Jiaming, et al.
Publicado: (2023)

Embracing the principles of practice transfer to get the word out on the new metabolic dysfunction-associated steatotic liver disease nomenclature
por: Carr, Rotonya M.
Publicado: (2023)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
por: Nagai, Koki, et al.
Publicado: (2023)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
por: Wu, Yanrui, et al.
Publicado: (2023)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
por: Al-Shargi, Amani, et al.
Publicado: (2023)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
por: Vesković, Milena, et al.
Publicado: (2023)

Baicalin Inhibits Ferroptosis in Intracerebral Hemorrhage
por: Duan, Lining, et al.
Publicado: (2021)

Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia–reperfusion
por: Mosbah, I Ben, et al.
Publicado: (2010)

The Effect of Fibroblast Growth Factor 15 Signaling in Non-Steatotic and Steatotic Liver Transplantation from Cardiocirculatory Death
por: Avalos-de León, Cindy G., et al.
Publicado: (2019)

Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers
por: Haq, Adeel, et al.
Publicado: (2023)

Endothelial Dysfunction in Steatotic Human Donor Livers: A Pilot Study of the Underlying Mechanism During Subnormothermic Machine Perfusion
por: Beijert, Irene, et al.
Publicado: (2018)

Study on the liver Drug’s dominant metabolic enzymes for six effective components of the Huang qi Liuyi decoction
por: Wang, Qun, et al.
Publicado: (2023)

Ferroptosis and Acute Kidney Injury (AKI): Molecular Mechanisms and Therapeutic Potentials
por: Feng, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ch7jtdoeq6k1frtao3i7gmrgd